IMV Share Price

Open 0.73 Change Price %
High 0.73 1 Day 0.01 1.39
Low 0.68 1 Week 0.00 0.00
Close 0.73 1 Month 0.00 0.00
Volume 73405 1 Year 0.00 0.00
52 Week High 0.05
52 Week Low 0.01
IMV Important Levels
Resistance 2 0.78
Resistance 1 0.76
Pivot 0.71
Support 1 0.70
Support 2 0.68
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
DDX 0.50 100.00%
OEC 0.02 100.00%
OEC 0.02 100.00%
AZU 0.02 100.00%
AZU 0.02 100.00%
DXE 0.02 100.00%
BVQ 0.02 100.00%
MKR 0.02 100.00%
SBX 0.02 100.00%
SBX 0.02 100.00%
More..
CVE Canada Top Losers Stocks
RGI 0.02 -50.00%
RGI 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
ASL 0.16 -42.86%
ASL 0.16 -42.86%
ASL 0.16 -42.86%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
More..

Immunovaccine Inc (CVE: IMV)

IMV Technical Analysis 3
As on 25th Nov 2014 IMV Share Price closed @ 0.73 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.78 & Sell for SHORT-TERM with Stoploss of 0.76 we also expect STOCK to react on Following IMPORTANT LEVELS.
IMV Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
IMV Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.imvaccine.com
IMV Address
IMV
1344 Summer Street
Suite 412
Halifax, NS B3H 0A8
Canada
Phone: 902-492-1819
Fax: 902-492-0888
Interactive Technical Analysis Chart Immunovaccine Inc ( IMV CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Immunovaccine Inc
IMV Business Profile
Immunovaccine Inc., a clinical-stage biopharmaceutical company, discovers and develops activators of the immune system to treat cancer and prevent infectious diseases. The company develops its products based on DepoVax vaccine-adjuvanting platform, a vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Its product candidates include DPX-Survivac, a therapeutic cancer vaccine, which has completed Phase I clinical trials for the treatment of ovarian and brain cancer; and DPX-0907, a therapeutic cancer vaccine that has completed Phase I clinical trials for the treatment of breast, ovarian, and prostate cancer. The company also develops pre-clinical stage vaccine product candidates for infectious diseases, including respiratory syncytial virus and anthrax. In addition, its product pipeline consists of DepoVax-validating partnered programs for addiction medicine and animal health. Immunovaccine Inc. was founded in 2000 and is headquartered in Halifax, Canada.